1. Home
  2. AVXL

as of 12-05-2025 3:46pm EST

$4.37
$0.08
-1.91%
Stocks Health Care Biotechnology: Biological Products (No Diagnostic Substances) Nasdaq

Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.

Chart Type:
Time Range:
Founded: 2004 Country:
United States
United States
Employees: N/A City: NEW YORK
Market Cap: 397.6M IPO Year: N/A
Target Price: $22.00 AVG Volume (30 days): 4.6M
Analyst Decision: Strong Buy Number of Analysts: 3
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -0.54 EPS Growth: N/A
52 Week Low/High: $2.86 - $14.44 Next Earning Date: 11-25-2025
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): -49.23%

AI-Powered AVXL Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated 3 days ago

AI Recommendation

hold
Model Accuracy: 69.33%
69.33%
Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Latest Anavex Life Sciences Corp. News

AVXL Breaking Stock News: Dive into AVXL Ticker-Specific Updates for Smart Investing

All AVXL News

Share on Social Networks: